Andrew D. Goldberg
CIK: 0001827722
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
2.4K shares- - Jun 12, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct3K shares- - Apr 18, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectPerformance Restricted Stock Unit (PRSU)
11.7M shares- - Apr 18, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectRestricted Stock Unit (RSU)
1.8M shares- - Apr 18, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
3.6M shares- - Jun 13, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct3.4K shares- - Jun 12, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
3K shares- - Jun 12, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
4.5K shares- - Mar 7, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct7K shares at avg. $12.89$90K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 |  TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,837 | - | - | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,417 | - | - | Direct |
| Jun 12, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 2,954 | - | $0 | Direct |
| Apr 18, 2026 |  ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Performance Restricted Stock Unit (PRSU) | 11,706,270 | - | - | Direct |
| Apr 18, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Restricted Stock Unit (RSU) | 1,800,965 | - | - | Direct |
| Apr 18, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 3,601,929 | - | - | Direct |
| Jun 13, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 3,350 | - | - | Direct |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,954 | - | - | Direct |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 4,540 | - | - | Direct |
| Mar 7, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 7,000 | $12.89 | $90,230 | Direct |
1-10 of 10 transactions
About Goldberg Andrew D.
Goldberg Andrew D. (SEC CIK 0001827722) files insider reports with the SEC as Director of Tarsus Pharmaceuticals, Inc. (TARS) and CEO and President of ACHIEVE LIFE SCIENCES, INC. (ACHV).
Signal8 holds 6 ownership filings by Goldberg Andrew D. (1 Form 3, 5 Form 4), filed between Mar 11, 2025 and Jun 29, 2026. Those filings report 10 transactions, from Mar 7, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Goldberg Andrew D.'s filings is in IRVINE, CA.
Recent filings by Goldberg Andrew D.
- Jun 25, 2026: Grants or awards of TARS derivative securities (2 lines, Form 4, code A).
- Jun 12, 2026: Option exercise of TARS shares (Form 4, code M).
- Apr 18, 2026: Grants or awards of ACHV derivative securities (3 lines, Form 4, code A).
- Jun 13, 2025: Option exercise of TARS shares (Form 4, code M).
- Jun 12, 2025: Grants or awards of TARS derivative securities (2 lines, Form 4, code A).
Other insiders filing for Tarsus Pharmaceuticals, Inc. (TARS)
- PYOTT DAVID E I, Director
- YARNO WENDY L, Director
- LINK WILLIAM J PHD, Director
- Azamian Bobak R., President/CEO and Board Chair
- Lin Elizabeth Yeu, Chief Medical Officer
- Neervannan Seshadri, Chief Operating Officer